TEXAS RESEARCH: ALZHEIMER’S DISEASE VACCINE IN THE WORKS 

April 1, 2019

This small bit of Alzheimer’s news out of the University of Texas Southwestern Medical Center slipped under the radar late last year. The researchers there revealed that an experimental vaccine that could hold off Alzheimer’s disease showed promising results in animal testing trials.  

Testing Process 

In the journal Alzheimer’s Research & Therapy, their research revealed that testing in mice showed that the vaccine safely prevented the buildup of substances in brains associated with the fatal disease. The mice were given an active full-length DNA amyloid-β peptide immunization. Amyloid-β is present in the plaques and tangles that are the hallmark of Alzheimer’s disease. 

The mice that were given the immunization showed a 40% reduction of active full-length DNA amyloid-β peptide and a 25–50% reduction of total tau and different phosphorylated tau molecules. According to the research, the results definitively showed the reduction of both amyloid and tau aggregation and accumulation. 

The study noted that there has been research in monkeys and rabbits, and the researchers hope the vaccine will progress to human trials. If proven safe and effective in humans, the study’s senior author, Dori Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, shared with USA Today that it could slice the number of dementia diagnoses in half. 

Goal of Disease Prevention 

As we’ve discussed here, dementia is a term used to broadly describe symptoms of cognitive decline, with Alzheimer’s disease among the most common cause of dementia.  

The researchers at the University of Texas Southwestern Medical center believe the vaccine could extend lives by preventing the disease from developing. 

“If the onset of the disease could be delayed by even five years, that would be enormous for patients and their families,” Lambracht-Washington said in a statement. “The number of dementia cases would drop by half.” 

Progress in the Right Direction 

This study punctuates major progress toward a safe and effective vaccine. Previous attempts to find an Alzheimer’s vaccine either caused harmful side effects, such as dangerous brain inflammation, or the approaches were ineffective, Lambracht-Washington reported. 

This new vaccine works by promoting the body to produce antibodies inhibiting the buildup of amyloid and tau, two proteins that are hallmarks of the degenerative brain disease. It is one of several potential treatments targeted at reducing the buildup of these proteins before they become deadly plaques and tangles in the brain. 

According to the University of Texas, about 5.7 million Americans have Alzheimer’s disease. That number is expected to double by 2050. 

If you would like to read more, check out our blog post “Possible New Alzheimer’s Treatment Discovered,” about ongoing research at Yale University.

Other Articles

  • Breakthrough: Blood Test Makes it Possible to Track Alzheimer’s Advancement 
    A connection between Neurofilament light (NfL) levels present in the blood and Alzheimer’s disease was recently made in a study released by the JAMA Network.
  • New Study Might Diagnose CTE in Brains of the Living
    A recent study published in the New England Journal of medicine revealed that brain scans of more than two dozen former NFL players found that the men had abnormal levels of the protein linked to chronic traumatic encephalopathy (C.T.E.), the degenerative brain disease we have discussed here that’s associated with repeated hits to the head.  
  • JUST PUT DOWN THE SUPPLEMENTS 
    There have long been debates among established medical authorities and supplement manufacturers, especially when it comes to treating cognitive decline. Are the myriad of supplements currently on the market a genie in a bottle? Or is it better to focus on leading a healthy, balanced lifestyle? 
  • BREAKING NEWS: Promising Alzheimer’s Drug Fails in Late-Stage Human Trials 
    Another big blow came to the Alzheimer’s research community late last month when pharmaceutical company Biogen and Eisai Co. announced on March 22 that they would terminate two late-stage studies of
  • Could a Noninvasive Eye Exam Preemptively Diagnose Alzheimer’s Disease? 
    That’s what a recent study conducted at the Duke Eye Center suggests. The study of more than 200 people, published on March 11 in the journal Ophthalmology Retina, proposes that a quick, noninvasive
  • Tom Seaver Diagnosis Reignites Lyme Disease & Dementia Debate
    AN ARTICLE IN The New York Times recently revealed that Tom Seaver, legendary pitcher and the most prominent player in New York Mets history, is stepping back from public life because of advancing dementia. It was recently discovered that Seaver, 74, has dementia. However, for many years he suffered from the effects of Lyme disease, which can cause cognitive problems similar to dementia.